MRTX RSI Chart
Last 7 days
-0.8%
Last 30 days
1.8%
Last 90 days
5.6%
Trailing 12 Months
36.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 18.9M | 27.2M | 38.2M | 0 |
2022 | 67.0M | 48.8M | 30.6M | 12.4M |
2021 | 0 | 0 | 49.3M | 85.2M |
2020 | 5.9M | 8.4M | 10.9M | 13.4M |
2019 | 4.7M | 5.3M | 6.3M | 3.3M |
2018 | 5.6M | 8.0M | 10.5M | 12.9M |
2011 | 0 | 0 | 0 | 3.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 23, 2024 | carter bruce l a | back to issuer | - | - | -17,273 | - |
Jan 23, 2024 | sharp shalini | back to issuer | - | - | -16,222 | - |
Jan 23, 2024 | hickey benjamin | back to issuer | - | - | -117,028 | evp, chief commercial officer |
Jan 23, 2024 | johnson craig a | back to issuer | - | - | -17,273 | - |
Jan 23, 2024 | baum charles m | back to issuer | - | - | -237,871 | founder, president, and ceo |
Jan 23, 2024 | cherrington julie m | back to issuer | - | - | -11,252 | - |
Jan 23, 2024 | sandler alan b. | back to issuer | - | - | -79,865 | chief medical officer |
Jan 23, 2024 | boxer capital, llc | back to issuer | - | - | -3,201,440 | - |
Jan 23, 2024 | martinez maria e | back to issuer | - | - | -17,273 | - |
Jan 23, 2024 | boxer capital, llc | back to issuer | - | - | -3,658,100 | - |
Which funds bought or sold MRTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 08, 2024 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | sold off | -100 | -3,777,800 | - | -% |
May 08, 2024 | Bell Investment Advisors, Inc | sold off | -100 | -529 | - | -% |
May 08, 2024 | Calamos Advisors LLC | sold off | -100 | -16,321,200 | - | -% |
May 08, 2024 | US BANCORP \DE\ | sold off | -100 | -208,270 | - | -% |
May 08, 2024 | PROFUND ADVISORS LLC | sold off | -100 | -1,473,330 | - | -% |
May 08, 2024 | Russell Investments Group, Ltd. | sold off | -100 | -15,628 | - | -% |
May 08, 2024 | KBC Group NV | sold off | -100 | -56,000 | - | -% |
May 08, 2024 | BCK Capital Management LP | sold off | -100 | -940,000 | - | -% |
May 08, 2024 | ProShare Advisors LLC | sold off | -100 | -263,318 | - | -% |
May 07, 2024 | Susquehanna Portfolio Strategies, LLC | sold off | -100 | -9,089,800 | - | -% |
Unveiling Mirati Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Mirati Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 47.0B | 6.8B | -7.88 | 6.87 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.2B | 2.0B | -57.69 | 9.56 | ||||
BMRN | 15.5B | 2.5B | 75.54 | 6.28 | ||||
INCY | 12.0B | 3.8B | 16.12 | 3.19 | ||||
MID-CAP | ||||||||
BBIO | 5.4B | 107.9M | -9.84 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.38 | 9.86 | ||||
AXSM | 3.5B | 251.0M | -11.8 | 13.94 | ||||
ARWR | 3.1B | 240.7M | -10.34 | 12.18 | ||||
ACAD | 2.5B | 726.4M | -40.84 | 3.45 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 28.42 | 4.5 | ||||
NVAX | 627.0M | 983.7M | -1.15 | 0.64 | ||||
CRBP | 467.5M | 881.7K | -13.85 | 481.06 | ||||
INO | 260.8M | 4.9M | -1.93 | 53.59 | ||||
IBIO | 6.4M | 2.1M | -0.24 | 2.14 |
Mirati Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Revenue | 19.8% | 16,400,000 | 13,690,000 | 7,167,000 | 934,000 | 5,431,000 | 5,362,000 | 2,830,500 | 299,000 | 71,793,000 | 1,708,000 | 11,424,000 | 7,791,333 | 4,158,667 | 526,000 | 988,000 | 577,000 | 1,244,000 | 3,459,000 | - | - | 9,467,000 |
Operating Expenses | -6.2% | 188,454,000 | 200,960,000 | 200,990,000 | 212,657,000 | 191,874,000 | 182,567,000 | 184,927,000 | 197,374,000 | 151,292,000 | 108,043,000 | 100,102,000 | 84,862,000 | 89,754,000 | 75,173,000 | 58,047,000 | 48,218,000 | 44,002,000 | 33,131,000 | 28,939,000 | 28,670,000 | 24,813,000 |
S&GA Expenses | -4.6% | 72,001,000 | 75,490,000 | 73,490,000 | 70,821,000 | 60,798,000 | 54,228,000 | 53,951,000 | 43,535,000 | 35,183,000 | 25,338,000 | 20,249,000 | 19,779,000 | 18,046,000 | 12,232,500 | 10,685,000 | 9,894,000 | 9,762,000 | 6,373,000 | 5,313,000 | 4,841,000 | 5,154,000 |
R&D Expenses | -7.6% | 114,766,000 | 124,187,000 | 126,683,000 | 141,236,000 | 131,076,000 | 128,339,000 | 130,976,000 | 153,839,000 | 116,109,000 | 82,705,000 | 79,853,000 | 65,083,000 | 71,708,000 | 62,940,500 | 47,362,000 | 38,324,000 | 34,240,000 | 26,758,000 | 23,626,000 | 23,829,000 | 19,659,000 |
EBITDA Margin | 29.1% | -19.19 | -27.06 | -39.01 | -59.30 | -21.06 | -13.63 | -10.08 | -8.00 | -6.21 | -26.67 | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | 254,000 | 254,000 | - | - | - | 3,299,000 | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -Infinity% | -161,904,000 | - | - | -202,221,000 | -173,307,000 | - | - | -199,620,000 | -76,755,000 | -101,087,000 | -87,336,000 | - | - | - | - | - | - | - | - | - | - |
EBT Margin | 29.0% | -19.30 | -27.20 | -39.18 | -59.53 | -21.15 | -13.69 | -10.12 | -8.02 | -6.23 | -26.72 | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 8.5% | -161,904,000 | -176,913,000 | -184,586,000 | -202,475,000 | -173,561,000 | -176,445,000 | -188,386,000 | -199,620,000 | -80,054,000 | -101,087,000 | -87,336,000 | -82,859,000 | -86,655,000 | -72,376,000 | -54,273,000 | -45,695,000 | -40,912,000 | -28,272,000 | -27,568,000 | -27,869,000 | -14,709,000 |
Net Income Margin | 29.8% | -19.01 | -27.09 | -39.01 | -59.57 | -26.98 | -15.25 | -11.10 | -8.07 | -8.42 | -26.72 | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -8.8% | -143,749,000 | -132,122,000 | -190,451,000 | -129,610,000 | -139,049,000 | -145,153,000 | -161,609,000 | -140,634,000 | -49,041,000 | -77,927,000 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | 23.5% | 1,130 | 915 | 1,034 | 1,203 | 1,303 | 1,280 | 1,421 | 1,589 | 1,253 | 1,356 | 1,381 | 1,476 | 620 | 664 | 713 | 432 | 471 | 501 | 309 | 228 | 248 |
Current Assets | 26.5% | 1,036 | 819 | 939 | 1,109 | 1,226 | 1,203 | 1,343 | 1,508 | 1,172 | 1,278 | 1,304 | 1,404 | 595 | 654 | 705 | 424 | 465 | 496 | 306 | 227 | 246 |
Cash Equivalents | 99.2% | 259 | 130 | 242 | 235 | 299 | 266 | 305 | 414 | 243 | 281 | 330 | 886 | 131 | 132 | 205 | 47.00 | 92.00 | 252 | 75.00 | 33.00 | 117 |
Inventory | 133.2% | 20.00 | 9.00 | 4.00 | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -4.9% | 16.00 | 17.00 | 17.00 | 18.00 | 18.00 | 17.00 | 17.00 | 16.00 | 14.00 | 12.00 | 9.00 | 8.00 | 6.00 | 3.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -1.5% | 183 | 186 | 171 | 206 | 174 | 168 | 172 | 192 | 169 | 227 | 121 | 115 | 69.00 | 59.00 | 57.00 | 50.00 | 36.00 | 29.00 | 26.00 | 27.00 | 23.00 |
Current Liabilities | -1.9% | 137 | 140 | 125 | 159 | 127 | 119 | 124 | 144 | 122 | 181 | 77.00 | 71.00 | 67.00 | 58.00 | 56.00 | 49.00 | 35.00 | 28.00 | 25.00 | 26.00 | 22.00 |
Shareholder's Equity | 29.8% | 946 | 729 | 863 | 997 | 1,129 | 1,112 | 1,249 | 1,397 | 1,084 | 1,129 | 1,259 | 1,361 | 551 | 605 | 656 | 382 | 434 | 472 | 284 | 202 | 225 |
Retained Earnings | -5.8% | -2,976 | -2,814 | -2,637 | -2,452 | -2,250 | -2,076 | -1,900 | -1,712 | -1,512 | -1,432 | -1,265 | -1,130 | -1,029 | -941 | -858 | -772 | -699 | -645 | -599 | -559 | -530 |
Additional Paid-In Capital | 10.7% | 3,924 | 3,545 | 3,502 | 3,453 | 3,386 | 3,185 | 3,145 | 3,100 | 2,587 | 2,552 | 2,516 | 2,481 | 1,570 | 1,535 | 1,505 | 1,145 | 1,124 | 1,108 | 874 | 751 | 746 |
Shares Outstanding | 20.2% | 70.00 | 58.00 | 58.00 | 58.00 | 56.00 | 56.00 | 55.00 | 55.00 | 52.00 | 51.00 | 51.00 | 45.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | 3,700 | - | - | - | 7,400 | - | - | - | 4,433 | - | - | - | 2,907 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | -9.4% | -143,713 | -131,400 | -190,182 | -128,800 | -137,809 | -143,492 | -160,469 | -137,985 | -47,032 | -93,367 | -110,416 | -76,421 | -76,763 | -59,343 | -59,004 | -41,902 | -32,874 | -38,468 | -34,482 | -20,795 | -20,172 |
Share Based Compensation | 13.1% | 44,553 | 39,399 | 46,961 | 61,607 | 42,992 | 38,684 | 42,905 | 33,878 | 26,933 | 27,969 | 24,722 | 21,743 | 21,750 | 20,787 | 21,567 | 16,711 | 15,106 | 12,589 | 11,131 | 4,262 | 4,058 |
Cashflow From Investing | -500.4% | -62,194 | 15,532 | 195,151 | 59,297 | 13,945 | 103,006 | 49,555 | -170,838 | 704 | 36,761 | -455,528 | -59,340 | 64,157 | -22,447 | -122,227 | -6,939 | -128,066 | -5,927 | -35,208 | -63,683 | 28,762 |
Cashflow From Financing | 8609.3% | 334,700 | 3,843 | 1,727 | 5,920 | 157,105 | 1,392 | 2,527 | 479,282 | 8,232 | 7,823 | 9,885 | 889,889 | 12,351 | 9,273 | 339,201 | 3,473 | 1,072 | 221,882 | 111,601 | 462 | 2,157 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Total revenue | $ 16,400 | $ 5,431 | $ 37,257 | $ 11,502 |
Revenue | ||||
Total revenue | 16,400 | 5,431 | 37,257 | 11,502 |
Operating expenses | ||||
Cost of product revenue | 1,428 | 0 | 3,011 | 0 |
Cost of product revenue - intangible asset amortization | 259 | 0 | 776 | 0 |
Research and development | 114,766 | 131,076 | 365,636 | 390,391 |
Selling, general and administrative | 72,001 | 60,798 | 220,981 | 168,977 |
Total operating expenses | 188,454 | 191,874 | 590,404 | 559,368 |
Loss from operations | (172,054) | (186,443) | (553,147) | (547,866) |
Other income, net | 10,150 | 13,136 | 29,744 | 9,728 |
Loss before income taxes | (161,904) | (173,307) | (523,403) | (538,138) |
Income tax expense | 0 | 254 | 0 | 254 |
Net loss | (161,904) | (173,561) | (523,403) | (538,392) |
Unrealized gain (loss) on available-for-sale investments | 106 | (1) | 2,175 | (5,712) |
Foreign currency translation adjustment | 59 | (9,485) | (6) | (9,485) |
Comprehensive loss | $ (161,739) | $ (183,047) | $ (521,234) | $ (553,589) |
Basic net loss per share (USD per share) | $ (2.49) | $ (3.09) | $ (8.66) | $ (9.66) |
Diluted net loss per share (USD per share) | $ (2.49) | $ (3.09) | $ (8.66) | $ (9.66) |
Weighted average common shares outstanding, basic (shares) | 64,993,079 | 56,219,416 | 60,419,755 | 55,747,205 |
Weighted average common shares outstanding, diluted (shares) | 64,993,079 | 56,219,416 | 60,419,755 | 55,747,205 |
Product Revenue | ||||
Total revenue | $ 16,400 | $ 0 | $ 36,056 | $ 0 |
Revenue | ||||
Total revenue | 16,400 | 0 | 36,056 | 0 |
License and Collaboration Revenue | ||||
Total revenue | 0 | 5,431 | 1,201 | 11,502 |
Revenue | ||||
Total revenue | $ 0 | $ 5,431 | $ 1,201 | $ 11,502 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 258,718 | $ 235,260 |
Short-term investments | 717,716 | 848,577 |
Accounts receivable, net | 14,651 | 865 |
Inventory | 20,156 | 3,020 |
Other current assets | 24,839 | 21,239 |
Total current assets | 1,036,080 | 1,108,961 |
Property and equipment, net | 16,046 | 17,540 |
Intangible asset, net | 14,138 | 14,914 |
Long-term investment | 3,559 | 3,465 |
Right-of-use asset | 35,066 | 36,122 |
Other long-term assets | 24,819 | 21,645 |
Total assets | 1,129,708 | 1,202,647 |
Current liabilities | ||
Accounts payable | 37,961 | 38,861 |
Accrued liabilities | 99,418 | 120,587 |
Total current liabilities | 137,379 | 159,448 |
Lease liability | 42,203 | 43,661 |
Other liabilities | 3,661 | 3,022 |
Total liabilities | 183,243 | 206,131 |
Commitments and contingencies (see Note 11) | ||
Shareholders' equity | ||
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both September 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 authorized; 70,111,309 and 57,854,559 issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 70 | 58 |
Additional paid-in capital | 3,924,237 | 3,453,066 |
Accumulated other comprehensive loss | (1,550) | (3,719) |
Accumulated deficit | (2,976,292) | (2,452,889) |
Total shareholders' equity | 946,465 | 996,516 |
Total liabilities and shareholders' equity | $ 1,129,708 | $ 1,202,647 |